Panacos Pharmaceuticals, Inc. PANC Company Overview 

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Panacos Pharmaceuticals, Inc. PANC Company Overview 

Stock Message Board http://investorshangout.com/search?q=PANC&...mp;yt1=Go!

Panacos Pharmaceuticals, Inc. PANC Current Price and Quotes
Last Price 0.007
Previous Close 0.007 Open 0.01
Daily Range 0.01 - 0.007 52wk Range 0.014 - 0.0011
Volume 8,507 Dividend N/A
Average Vol (3m) 16,857 Yield N/A
Panacos Pharmaceuticals, Inc. PANC

Panacos Pharmaceuticals, Inc. PANC
Panacos Pharmaceuticals, Inc. PANC
Financial Reportings and Disclosures

Reporting Status Dark: Alternative Reporting Standard
Deregistered a/o Mar 19, 2009
Audited Financials Not Available
Latest Report Sep 30, 2008 10-Q
CIK 0001040017
Fiscal Year End 12/31
OTC Marketplace OTC Pink No Information
Profile Data

SIC - Industry Classification 2836 - Biological products, except diagnostic
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts

John R. Barr President, CEO
Thomas T. Higgins CFO
Company Directors

Not Available
Company Notes

Formerly=V.I. Technologies, Inc. until 8-05
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Panacos Pharmaceuticals, Inc. PANC
PANC Security Details

Share Structure

Market Value1 $375,481 a/o Sep 12, 2013
Shares Outstanding 53,640,136 a/o Jul 31, 2008
Float Not Available
Authorized Shares Not Available
Par Value  0.01
Shareholders

Shareholders of Record 185 a/o Mar 07, 2008
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.00) *  Mar 09, 2005
Security Notes

New Issue=6-98 3,000,000 shs at $12 by Cowen & Co. et al.
Note = deleted from NASDAQ on 03/19/09
Capital Change=shs decreased by 1 for 10 split. Pay date=03/15/2005.
Short Selling Data

Short Interest 0 (-100%)
Apr 15, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

American Stock Transfer & Trust Company

Panacos Pharmaceuticals, Inc. PANC Recent News

Panacos Pharmaceuticals, Inc. PANC Financials
PANC


PANC Panacos Pharmaceuticals, Inc. Research DD Guide

PANC Panacos Pharmaceuticals, Inc. Stock Message Board http://investorshangout.com/search?q=PANC&...mp;yt0=Go!
PANC Panacos Pharmaceuticals, Inc. Stock Quote http://www.otcmarkets.com/stock/PANC/quote
PANC Panacos Pharmaceuticals, Inc. Stock Chart http://www.otcmarkets.com/stock/PANC/chart
PANC Panacos Pharmaceuticals, Inc. Company Info http://www.otcmarkets.com/stock/PANC/company-info
PANC Panacos Pharmaceuticals, Inc. Recent News http://www.otcmarkets.com/stock/PANC/news
PANC Panacos Pharmaceuticals, Inc. Financials http://www.otcmarkets.com/stock/PANC/financials
PANC Panacos Pharmaceuticals, Inc. Filings and Disclosure http://www.otcmarkets.com/stock/PANC/filings
PANC Panacos Pharmaceuticals, Inc. Short Sales http://www.otcmarkets.com/stock/PANC/short-sales
PANC Panacos Pharmaceuticals, Inc. Insider Disclosure http://www.otcmarkets.com/stock/PANC/insider-transactions
PANC Panacos Pharmaceuticals, Inc. Research Reports http://www.otcmarkets.com/stock/PANC/research
PANC Panacos Pharmaceuticals, Inc. Summary http://finance.yahoo.com/q?s=PANC
PANC Panacos Pharmaceuticals, Inc. Historical Prices http://finance.yahoo.com/q/hp?s=PANC+Historical+Prices
PANC Panacos Pharmaceuticals, Inc. Interactive Chart http://finance.yahoo.com/echarts?s=PANC
PANC Panacos Pharmaceuticals, Inc. Basic Chart http://finance.yahoo.com/q/bc?s=PANC+Basic+Chart
PANC Panacos Pharmaceuticals, Inc. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PANC+Basic+Tech.+Analysis
PANC Panacos Pharmaceuticals, Inc. Headlines http://finance.yahoo.com/q/h?s=PANC+Headlines
PANC Panacos Pharmaceuticals, Inc. Press Releases http://finance.yahoo.com/q/p?s=PANC+Press+Releases
PANC Panacos Pharmaceuticals, Inc. Company Profile http://finance.yahoo.com/q/pr?s=PANC+Profile
PANC Panacos Pharmaceuticals, Inc. Key Statistics http://finance.yahoo.com/q/ks?s=PANC+Key+Statistics
PANC Panacos Pharmaceuticals, Inc. Industry http://finance.yahoo.com/q/in?s=PANC+Industry
PANC Panacos Pharmaceuticals, Inc. Major Holders http://finance.yahoo.com/q/mh?s=PANC+Major+Holders
PANC Panacos Pharmaceuticals, Inc. Insider Transactions http://finance.yahoo.com/q/it?s=PANC+Insider+Transactions
PANC Panacos Pharmaceuticals, Inc. Insider Roster http://finance.yahoo.com/q/ir?s=PANC+Insider+Roster
PANC Panacos Pharmaceuticals, Inc. Income Statement http://finance.yahoo.com/q/is?s=PANC
PANC Panacos Pharmaceuticals, Inc. Balance Sheet http://finance.yahoo.com/q/bs?s=PANC
PANC Panacos Pharmaceuticals, Inc. Cash Flow http://finance.yahoo.com/q/cf?s=PANC+Cash+Flow&annual
PANC Panacos Pharmaceuticals, Inc. Nasdaq http://www.nasdaq.com/symbol/PANC
PANC Panacos Pharmaceuticals, Inc. Market Watch http://www.marketwatch.com/investing/stock/PANC
PANC Panacos Pharmaceuticals, Inc. Bloomberg http://www.bloomberg.com/quote/PANC:US
PANC Panacos Pharmaceuticals, Inc. Morningstar http://quotes.morningstar.com/stock/s?t=PANC
PANC Panacos Pharmaceuticals, Inc. Bussinessweek http://investing.businessweek.com/research/st...icker=PANC
PANC Panacos Pharmaceuticals, Inc. Barchart http://www.barchart.com/quotes/stocks/PANC
PANC Panacos Pharmaceuticals, Inc. OTC Short Report http://otcshortreport.com/index.php?index=PANC
PANC Panacos Pharmaceuticals, Inc. Investopedia http://www.investopedia.com/markets/stocks/PANC/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading